Allergy immunotherapy: Future directions for the 2020s

Area of Science:

• Immunology
• Allergology
• Pharmacology

Background:

• Allergy immunotherapy (AIT), including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), is a recognized treatment for inhalant allergen sensitization.
• Current AIT methods require prolonged treatment durations, leading to inconvenience, high costs, and poor patient compliance.
• Unresolved issues include optimal dosing for SLIT-liquid preparations and efficacy of multiple allergen extracts.

Purpose of the Study:

• To review current challenges in AIT and explore novel approaches for enhancing treatment efficacy, safety, and convenience.
• To discuss emerging strategies in AIT, including alternative administration routes, adjuvants, and modified allergen molecules.

Main Methods:

• Review of existing literature on allergy immunotherapy.
• Analysis of ongoing research into new AIT strategies and technologies.
• Discussion of potential future directions for AIT practice.

Main Results:

• Several innovative approaches are under investigation to improve AIT.
• These include alternative administration routes, use of adjuvants (e.g., vitamin D, TLR agonists), modified allergen molecules (allergoids, recombinant technology), and improved patient-specific treatment matching.
• Environmental modifications, such as reducing cat allergen release, are also considered.

Conclusions:

• New AIT approaches hold promise for increasing effectiveness, safety, and convenience.
• The successful integration of these novel strategies into clinical practice will depend on robust efficacy data and resource availability for further research.